Salvinorin A Cyclodextrin Complex for Cerebral Vasospasm
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiac arrest, stroke, and subarachnoid hemorrhage lack effective medications that can be easily managed and administered to improve survival rates and reduce neurological injury, with existing opioid receptor agonists having significant side effects and limited clinical use due to their side effects and safety profiles.
Innovation Solution
A pharmaceutical composition of salvinorin A in an aqueous solution with 2-hydroxypropyl-cyclodextrin, which is administered to treat cerebral vasospasm, neurological injuries, and conditions associated with cardiac arrest, stroke, and cerebral hypoxia/ischemia, leveraging its rapid onset and ability to cross the blood-brain barrier without respiratory depression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If salvinorin A is used to treat neurological conditions, then therapeutic efficacy is improved, but water solubility is insufficient for intravenous delivery
Solution Approach 1:
The patent uses cyclodextrins as intermediary molecules to solubilize salvinorin A in aqueous solutions. The cyclodextrin forms inclusion complexes with the hydrophobic salvinorin A, allowing it to be delivered intravenously in water-based formulations without compromising therapeutic efficacy.
Solution Approach 2:
The patent changes the physical-chemical parameters of salvinorin A by forming molecular complexes with cyclodextrins, transforming it from a water-insoluble compound to one that can be dissolved in aqueous solutions at clinically relevant concentrations for intravenous administration.
2Reliability
If opioid KOR agonists are used to treat neurological conditions, then pain relief and neurological protection are achieved, but side effects such as respiratory depression and dysphoria increase
Solution Approach 1:
The patent extracts and utilizes only the beneficial neuroprotective and vasodilatory effects of KOR agonism while avoiding the harmful side effects associated with traditional opioid agonists. Salvinorin A selectively activates KOR to provide cerebral protection without causing respiratory depression or significant dysphoria.
Solution Approach 2:
The patent converts the previously problematic side effect profile of KOR agonists into a benefit by using salvinorin A, which provides the desired neuroprotective effects while having a favorable safety profile without respiratory depression, thereby transforming the class's historical harm into a therapeutic advantage.
3Reliability
If therapeutic hypothermia is used to treat post-cardiac arrest neurological injury, then neurological outcomes are improved, but treatment complexity and risk of complications increase
Solution Approach 1:
The patent extracts the neuroprotective benefit from complex therapies like therapeutic hypothermia and delivers it through a simpler pharmacological intervention. Salvinorin A provides comparable neurological protection without requiring intensive care infrastructure, temperature monitoring, or management of hypothermia-related complications.
Solution Approach 2:
The patent replaces expensive, resource-intensive therapeutic hypothermia equipment and infrastructure with a simple, single-dose pharmacological intervention that can be administered in any setting without specialized equipment, making treatment accessible in under-resourced facilities.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively dilates cerebral vessels, reduces infarct size, and improves survival and neurological outcomes by providing cerebrovasodilation and neuroprotection with minimal side effects, as demonstrated by its ability to preserve autoregulation and reduce mortality and long-term neurological deficits.
Implementation Method 1
an aqueous solution of salvinorin A and between 1% (w/v) and 50% (w/v) of a cyclodextrin, wherein the cyclodextrin is a 2-hydroxypropyl-cyclodextrin
Data Source
Figure 1A~1D
Figure 2
Figure 3
AI summary
The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering salvinorin compositions to treat diseases and disorders associated with vasoconstriction, vaso-occlusion, or disruption of blood flow and autoregulation. For example, salvinorin compositions may be administered to subjects with cardiac arrest, subarachnoid hemorrhage, stroke, cerebral vascular spasm, cerebral hypoxia/ischemia, cerebral artery occlusion, or any condition involved in autoregulation impairment.